Indian markets saw significant activity today, December 10, with several companies making headlines through strong stock market debuts, new contracts, and fundraising initiatives. E-commerce giant Meesho and precision component maker Aequs both listed with substantial premiums. Food delivery platform Swiggy began a major fundraising round, while infrastructure firms GPT Infra, Dilip Buildcon, and Highway Infrastructure secured new projects. Zydus Lifesciences also announced new product launches and strategic partnerships. ### New Listings Show Strong Market Appetite E-commerce firm Meesho made a strong stock market debut today, with its shares listing at a 46% premium over its issue price of ₹111. The stock opened at ₹162.50 on the National Stock Exchange (NSE) and ₹161.20 on the Bombay Stock Exchange (BSE). Meesh^[1]o reached a market capitalization of ₹72,751 crore. The com^[2]pany's initial public offering (IPO) raised ₹5,421.20 crore, including ₹4,250 crore from fresh shares and ₹1,171 crore from an offer for sale by existing shareholders. The IPO was h^[1][3]eavily oversubscribed, attracting bids 79.03 times the shares offered. Meesho plans ^[4]to use the raised capital to enhance its cloud infrastructure, invest in its AI and machine learning teams, and support marketing initiatives. In another n^[4][3]otable market entry, Aequs, a manufacturer of precision components, also listed today at a 13% premium. Its shares opened at ₹140 on both the NSE and BSE, against an issue price of ₹124. The stock later c^[5][6]limbed further, reaching ₹151.15 on the BSE and ₹151 on the NSE. Aequs's ₹922 crore IP^[7]O saw overwhelming investor demand, subscribing over 101 times. The funds from the fres^[8][7]h issue will go towards repaying loans, purchasing machinery, and exploring future acquisitions. ### Swiggy Seeks $1.1 ^[7]Billion, Infrastructure Firms Win Big Food delivery major Swiggy launched a Qualified Institutional Placement (QIP) on December 9, aiming to raise ₹10,000 crore, equivalent to approximately $1.1 billion. The floor price for the Q^[9][10]IP is set at ₹390.51 per share, which is a discount from its previous closing price. Swiggy intends to allocate ^[11][12]₹4,475 crore to expand its quick commerce platforms, including darkstores and warehouses. Another ₹2,340 crore will be ^[11][13]invested in brand marketing and promotion, with ₹985 crore earmarked for cloud infrastructure. Swiggy's shares were closely watc^[11][13]hed today, gaining nearly 3% following the announcement. GPT Infraprojects was declared t^[11][13]he lowest bidder (L1) for a significant project valued at ₹199.17 crore from the North Eastern Railway in Gorakhpur, Uttar Pradesh. The contract involves constructing ^[14][15]bridges over the Rapti River, including substructure, superstructure fabrication, and launching works for Bridge No. 247 and Bridge No. 287. This news drove GPT Infraprojects s^[14][15]hares up by as much as 10% today. The company recently reported a 23.^[15][16]65% increase in consolidated net profit, reaching ₹21.80 crore in Q2 FY26. Dilip Buildcon secured a major Mine ^[14]Developer and Operator (MDO) contract worth ₹5,000 crore from the National Aluminium Company Limited (NALCO) for the Pottangi Bauxite Mines. This 25-year contract covers engineerin^[17][18]g, procurement, and construction (EPC) work for the first three years, valued at ₹1,750 crore. Mining operations will then continue for ^[19]the remaining 22 years, valued at ₹3,250 crore. The Letter of Award was received today, fol^[19]lowing NALCO's board approval on December 9. Highway Infrastructure Limited (HIL) annou^[20][21]nced it secured a ₹328.78 crore contract from the National Highways Authority of India (NHAI). The one-year contract involves operating and ^[22]collecting tolls at the Kaza Fee Plaza on the Chilakaluripet–Vijayawada stretch of National Highway 16 in Andhra Pradesh. This new order significantly boosted HIL's tota^[22][23]l order book to ₹1,078 crore as of today. HIL shares rallied up to 10% on the news. ### Zy^[24][23]dus Lifesciences Expands Portfolio, Anupam^[25] Rasayan Eyes US Growth Zydus Lifesciences launched "Zyrifa," a biosimilar for Denosumab, today for cancer patients. This biosimilar aims to treat osteoporosis and pr^[26][27]event skeletal complications in cancer patients and is priced at ₹12,495. In a separate development yesterday, Zydus announce^[26][27]d a strategic partnership with Germany-based Formycon AG. This collaboration grants Zydus exclusive licensing^[28][29] and supply rights for FYB206, a biosimilar of the immunotherapy drug Keytruda, in the US and Canadian markets. These announcements led to a rise in Zydus Life sha^[28][30]res today. Specialty chemicals manufacturer Anupam Rasayan an^[29][30]nounced its plan to acquire US-based Jayhawk Fine Chemicals Corporation for $150 million. The enterprise value of the deal is approximately $^[31][32]134 million. This acquisition marks Anupam Rasayan's entry into ^[31][33]onshore manufacturing in the United States, expanding its global contract development and manufacturing organization (CDMO) presence. Anupam Rasayan's shares gained 3% today following t^[31][32]he news. The company also reported strong Q2 FY26 results, w^[34][33]ith a consolidated net profit of ₹44.39 crore, a 30.41% increase quarter-on-quarter, and revenue of ₹739.19 crore, up 51% sequentially.

AI Insights Hub